Juniper Publishers Journal of Cardiology and Cardiovascular Therapy

JUNIPER PUBLISHERS - OPEN ACCESS JOURNAL OF CARDIOLOGY & CARDIOVASCULAR THERAPY Abstract Background: Double or triple antiplatelet therapy is a guideline mandated therapy for patients who undergo Percutaneous Coronary Intervention (PCI). However, there exists inter-individual variability in drug response to the antiplatelet agents leading to recurrent thrombotic events. We sought to study the efficacy and variability of thienopyridines (clopidogrel and prasugrel), ticagrelor and triple antiplatelet therapy in Post-PCI percutaneous coronary intervention (PCI) patients using AggreGuide A-100 platelet aggregometer, a point-of-care-test (POCT) device using laser light scattering technique. Methods: It was a single-centred prospective trial, included 405 patients who underwent PCI. Platelet reactivity was assessed by grading of platelet activity index (PAI) and considered as high on treatment platelet reactivity (HTPR) if PAI >5. Results: Patients on clopido

JUNIPER PUBLISHERS - OPEN ACCESS JOURNAL OF CARDIOLOGY & CARDIOVASCULAR THERAPY Keywords Keywords: Stroke; Coronary artery disease; Paraplegia; Tetraplegia Opinion Spinal cord injury (SCI) is a devastating, life-changing condition causing paralysis and sensory impairment as well as autonomic dysfunction. In addition, evidence documents a state of chronic inflammation in individuals with SCI [ 1 - 4 ]. Importantly, chronic inflammation is a significant cardiovascular disease risk factor. Furthermore, paralysis can lead to a relatively sedentary life style and a consequent reduction in physical work capacity [ 58 ]. Other consequences of inactivity are a higher body weight, a higher percentage of body fat [ 9 , 10 ], skeletal muscle dysfunction [ 11 - 14 ] and a lower forced vital capacity [ 15 - 17 ]. Autonomic dysfunction involves an abnormal and unstable regulation of the of the heart and vasculature [ 18 ].

JUNIPER PUBLISHERS - OPEN ACCESS JOURNAL OF CARDIOLOGY & CARDIOVASCULAR THERAPY Abstract Hypertension is one the major preventable causes of death and morbidity. The prevalence of hypertension is approximately 30-35% at studies conducted in countries. Today; the role played by hypertension in the development of heart failure and coronary heart disease and the benefits of primary prevention with effective treatment have been clearly demonstrated. The significance of treatment of hypertension in terms of secondary prevention has also been established in patients with heart failure and coronary heart disease. By the current guidelines, hypertension treatment goals has been individualized and specific patient groups have also been amide to provide the highest benefit from therapy. Early identification and effective treatment of hypertension therefore has vital importance for both primary and secondary prevention. Keywords: Hypertension; Coronary artery disease; Heart f

JUNIPER PUBLISHERS - OPEN ACCESS JOURNAL OF CARDIOLOGY & CARDIOVASCULAR THERAPY Abstract Peripheral arterial disease (PAD) is the chronic and progressive deterioration of lower extremity arterial blood flow due to systemic atherosclerosis. Currently, PAD is considered not only a disorder of lower extremity circulation and but also a predictorofincreased mortality and morbidity. In prevalence surveys conducted in Turkey, the frequencyof PAD was found up to 20-30%, increasing with advancing age. The diagnosis of PAD can easily be made by the ankle brachial index measurement. The incidence of coronary artery disease and congestive heart failure is higherin individuals with PAD. In addition, in patients with coronary artery disease or congestive heart failure, cardiovascular mortality and all - cause mortality increases in the presence of PAD. In conclusion, PAD is a systemic disease and should be treated systematically and effectively in addition to interventional thera

JUNIPER PUBLISHERS - OPEN ACCESS JOURNAL OF CARDIOLOGY & CARDIOVASCULAR THERAPY Abstract Background: Antiplatelet therapy is the hallmark therapy for patients with coronary artery disease status post percutaneous coronary intervention (PCI) with stenting. Millions of patients are subjected to such intervention and therapy annually. However recently, attention has been raised against the use of PPIs regarding its potential to decrease the efficacy of clopidogrel. Even the U.S. Food and Drug Administration (FDA) has issued warnings regarding the related use of these medications. Objective: We have evaluated multiple studies in an effort to shed light into the ambiguity of concomitant use of PPIs and clopidogrel in relation to increase risk for myocardial infarction (MI). Method: A web-based literature search was conducted through PubMed and Scholar using the keywords "proton pump inhibitors,” "Myocardial infarction,” and "clopidogrel.” Of the available